Patents Assigned to CV Therapeutics
  • Patent number: 5663450
    Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 2, 1997
    Assignee: CV Therapeutics
    Inventors: George F. Schreiner, Louis G. Lange, III
  • Patent number: 5521303
    Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: May 28, 1996
    Assignee: CV Therapeutics, Inc.
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Dayton T. Reardan
  • Patent number: 5429937
    Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: July 4, 1995
    Assignee: CV Therapeutics
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Paula M. Kinnunen